NCT06902090View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

July 25, 2023

Study Completion Date

August 25, 2023

Conditions
Pain
Interventions
DRUG

Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)

IV, 30 mg

DRUG

Meloxicam Nanocrystal Injection (ANJESO®)

IV, 30 mg

Trial Locations (1)

Unknown

Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Yangtze River Pharmaceutical Group Co., Ltd.

INDUSTRY